Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells

Toxicology in Vitro

Volumn 21, Issue 5, 2007, Pages 855-862

  von Borstel Smith, Melinda ^a   Crofoot, Kristi ^a   Rodriguez Proteau, Rosita ^a   Filtz, Theresa M ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Anti epileptic drugs; Osteomalacia; Permeability; Vitamin D

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM ION; CARBAMAZEPINE; PHENYTOIN; VITAMIN D;

ARTICLE; CALCIUM ABSORPTION; CALCIUM TRANSPORT; CELL STRAIN CACO 2; CELL STRUCTURE; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; INTESTINE FUNCTION;

AMINES; ANTICONVULSANTS; BIOLOGICAL TRANSPORT, ACTIVE; BONE DISEASES; CACO-2 CELLS; CALCIUM; CARBAMAZEPINE; CELL MEMBRANE PERMEABILITY; CYCLOHEXANECARBOXYLIC ACIDS; EPITHELIAL CELLS; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; PHENYTOIN; VITAMIN D;

EID: 34247092549     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2007.02.008     Document Type: Article

References (23)

1. Aiba T., Susa M., Fukumori S., and Hashimoto Y. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180. Drug Metabolism and Pharmacokinetics 20 (2005) 268-274
2. Bikle D.D., Gee E.A., and Munson S.J. Effect of ethanol on intestinal calcium transport in chicks. Gastroenterology 91 (1986) 870-876
3. Black R.E., Williams S.M., Jones I.E., and Goulding A. Children who avoid drinking cow milk have low dietary calcium intakes and poor bone health. American Journal of Clinical Nutrition 76 (2002) 675-680
4. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., and Vogt T.M. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. New England Journal of Medicine 332 (1995) 767-773
5. Dent C.E., Richens A., Rowe D.J., and Stamp T.C. Osteomalacia with long-term anticonvulsant therapy in epilepsy. British Medical Journal 4 (1970) 69-72
6. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy and Behavior 5 Suppl. 2 (2004) S41-S47
7. Fleet J.C., and Wood R.J. Specific 1,25(OH)2D3-mediated regulation of transcellular calcium transport in Caco-2 cells. American Journal of Physiology 276 (1999) G958-G964
8. Giuliano A.R., and Wood R.J. Vitamin D-regulated calcium transport in Caco-2 cells: unique in vitro model. American Journal of Physiology 260 (1991) G207-G212
9. Gough H., Goggin T., Bissessar A., Baker M., Crowley M., and Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. The Quarterly Journal of Medicine 59 (1986) 569-577
10. Hahn T.J. Bone complications of anticonvulsants. Drugs 12 (1976) 201-211
11. Johannessen S.I., Battino D., Berry D.J., Bialer M., Kramer G., Tomson T., and Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring 25 (2003) 347-363
12. Jovani M., Barbera R., Farre R., and Martin de Aguilera E. Calcium, iron, and zinc uptake from digests of infant formulas by Caco-2 cells. Journal of Agricultural Food Chemistry 49 (2001) 3480-3485
13. Mandagere A.K., Thompson T.N., and Hwang K.K. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. Journal of Medicinal Chemistry 45 (2002) 304-311
14. McNamara J.O. Pharmacotherapy of the Epilepsies. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics 11th edition (2005), McGraw-Hill Medical Publishing Division., New York
15. Pack A.M. The association between antiepileptic drugs and bone disease. Epilepsy Currents 3 (2003) 91-95
16. Pack A.M., and Morrell M.J. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 15 (2001) 633-642
17. Rodriguez-Proteau R., Mata J.E., Miranda C.L., Fan Y., Brown J.J., and Buhler D.R. Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. Xenobiotica 36 (2006) 41-58
18. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Lown K.S., and Watkins P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Molecular Pharmacology 51 (1997) 741-754
19. Stephen L.J., McLellan A.R., Harrison J.H., Shapiro D., Dominiczak M.H., Sills G.J., and Brodie M.J. Bone density and antiepileptic drugs: a case-controlled study. Seizure 8 (1999) 339-342
20. Surendran N., Nguyen L.D., Giuliano A.R., and Blanchard J. Enhancement of calcium transport in the Caco-2 cell monolayer model. Journal of Pharmaceutical Sciences 84 (1995) 410-414
21. Valimaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., Makela P., and Tunninen R. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. Journal of Bone and Mineral Research 9 (1994) 631-637
22. Verrotti A., Greco R., Morgese G., and Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Annals of Neurology 47 (2000) 385-388
23. Xu Y., Hashizume T., Shuhart M.C., Davis C.L., Nelson W.L., Sakaki T., Kalhorn T.F., Watkins P.B., Schuetz E.G., and Thummel K.E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Molecular Pharmacology 69 (2006) 56-65